Ixekizumab (IL-17A blocker) shows a consistent long-term safety profile in treating psoriasis with 5+ years of drug exposure in a large pooled database including 17,003 patient-years of exposure .
Results of this integrated analysis of 11 clinical trials were presented by Prof. Kristian Reich (Georg-August-University Göttingen, Germany), who pointed out that when it comes to drugs with which we only have limited experience, it is essential to capture data about safety as early as possible from as many patients as possible. A pooled analysis was performed of 11 controlled and uncontrolled phase 1-3 studies using ixekizumab in psoriasis totalling >17,000 patient years of exposure.
Prof. Reich: “The absolute numbers of safety events are actually very low here; infections are among the most frequent, but you have to treat 100 patients for 1 year to see 1 event, and this is in the ballpark with other targeted therapies.” The incidence rate of serio...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies Next Article
Advances in target-oriented therapy: psoriatic arthritis »
Table of Contents: SPIN 2019
Aetiology: Triggers and Risk Factors
Advances in Therapy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.